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Abstract
The prevalence of HIV-1 integrase mutations related to resistance
to the next-generation integrase inhibitor (INI), dolutegravir
(DTG), was assessed in 440 INI-naı¨ve subjects and in 120 patients
failing a raltegravir (RTG)-containing regimen. Of the mutations
selected by DTG in vitro, S153FY was not detected in any isolate
while L101I and T124A were highly prevalent in both groups and
signiﬁcantly associated with non-B subtype. RTG-selected double
and triple mutants, mostly the G140S/Q148H variant, were
detected in only 32 (26.7%) RTG-treated patients. As L101I and
T124A do not appear to exert any major effect in vivo and double
and triple mutants resistant to DTG are infrequently selected by
RTG, DTG can be effectively used in INI-naı¨ve patients and may
retain activity in many patients failing RTG.
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Dolutegravir (DTG, formerly S/GSK1349572) is a next-gen-
eration HIV-1 and HIV-2 integrase inhibitor (INI) with an
apparently increased genetic barrier to resistance with
respect to ﬁrst-generation INIs such as raltegravir (RTG)
[1,2]. Although no data about selection of resistance by
DTG in vivo have been reported so far, in vitro drug resis-
tance selection experiments have shown that DTG selects
for a deﬁned set of integrase (IN) mutations (L101I, T124A,
S153FY), yet these appear to confer only limited (within 2.5-
fold) resistance to DTG in standard phenotypic assays [3].
Higher fold resistance levels to DTG have been documented
with the G118R mutant selected in vitro by the prototype
second-generation INI MK-2048 [1,4] and with some RTG-
selected HIV variants containing at least two IN mutations,
particularly those occurring at codon pairs 138/148, 140/148
and 148/155 [3,5]. In light of the possibility of using DTG as
a ﬁrst- or second-line INI, it is important to know how often
IN mutations potentially decreasing DTG activity occur in
the RTG-naı¨ve and RTG-treated patient population.
The roughly nationwide Italian HIV drug resistance data-
base ARCA (Antiretroviral Resistance Cohort Analysis,
http://www.hivarca.net) was searched to retrieve HIV-1 IN
sequences obtained from patients with available treatment
information. The sequences were grouped depending on
whether they were obtained from RTG-naı¨ve patients or
patients failing RTG-based therapy. For each patient, the ﬁrst
IN sequence obtained before RTG treatment and the ﬁrst
IN sequence obtained following at least 12 weeks of RTG
treatment were retained for further analysis, whichever avail-
able. Mutations putatively related to DTG resistance were
deﬁned from in vitro DTG resistance selection studies [3]
(group DTG-S) and from in vitro DTG activity data on MK-
2048-selected [1] (MK-2048-S) and RTG-selected [3,5]
(group RTG-S) mutants. The prevalence of DTG resistance
mutations in the two treatment groups was compared by
Fisher’s exact test. Subtyping of IN sequences was performed
through phylogenetic analysis by using the Kimura two-
parameter distance matrix and the neighbour joining method
as implemented in the PHYLIP software package version 3.69
(http://evolution.genetics.washington.edu/phylip.html). The
updated Los Alamos Laboratory HIV-1 subtype sequence ﬁle
was used as a reference (http://www.hiv.lanl.gov/content/
sequence/NEWALIGN/align.html#ref). The prevalence of
individual DTG resistance mutations in subtype B and non-B
isolates was also compared by Fisher’s exact test.
A total of 592 IN sequences obtained from 550 distinct
patients between 30 November 2006 and 14 November 2011
were available. Following the inclusion criteria, 440 and 120
sequences obtained from RTG-naı¨ve and RTG-pretreated
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patients, respectively, were analysed. Paired sequences obtained
before and after RTG treatment were available for only 10
patients, therefore only a cross-sectional comparison was per-
formed. Of the 550 distinct patients, 445 and 105 harboured a
subtype B and non-B virus, respectively. RTG treatment cases
were signiﬁcantly associated with subtype B virus (111/120 in
RTG-treated vs. 344/440 in RTG- naı¨ve patients, p < 0.001). In
the RTG-treated group, the median (IQR) duration of RTG
treatment at the time of IN genotyping was 70 (31–100) weeks.
Overall, 263 (59.8%) IN sequences from RTG-naı¨ve patients
and 68 (56.7%) IN sequences from RTG-treated patients har-
boured at least one of the DTG-S mutations (Table 1). Actu-
ally, only L101I and T124A were detected and their
prevalence in the two groups was not signiﬁcantly different.
The only double mutant detected (L101I/T124A) was also
evenly distributed with respect to RTG treatment and was
not among those reported in the original DTG resistance in vi-
tro selection experiments, namely T124A/S153F and T124A/
S153Y [3]. Interestingly, both L101A and T124A were more
common in non-B than in B subtype sequences (86.5% vs.
41.0% and 54.2% vs. 15.7%, respectively, when considering
RTG-naı¨ve patients; both p < 0.0001). The only MK-2048-S
mutation, G118R, was not detected in any of the IN sequences
and none of the mutations included in the RTG-S double or
triple mutants were detected in RTG-naı¨ve patients.
The three RTG resistance pathways based on substitu-
tions at codons 143, 148 and 155 [6], either alone or com-
bined with another pathway, were detected in 7 (5.8%), 34
(28.3%) and 32 (26.7%) cases, respectively, in RTG treatment
failure isolates. Notably, as many as 50 (41.7%) of the IN
sequences obtained at failure of RTG therapy, did not con-
tain any mutation at codons 143, 148 or 155. RTG-S double
or triple mutants were detected in 32 (26.7%) RTG-failing
patients and the difference in prevalence with respect to
RTG-naı¨ve patients reached statistical signiﬁcance for some,
particularly for the highly prevalent G140S/Q148H (Table 1).
Similar to two previous surveys carried out in Spain [7]
and France [8], this large study helps deﬁne the ﬁrst and sec-
ond-line INI use scenarios for DTG. A relevant proportion
of INI- naı¨ve subjects were found to harbour virus with
L101I and/or T124A, two of the four DTG-S mutations [3],
particularly in association with non-B subtype, as also docu-
mented in the Spanish patient population [7]. We could not
conﬁrm the increased rate of detection of T124A in RTG-
treated patients with respect to RTG-naı¨ve subjects,
reported in the French [8] but not in the Spanish [7] study.
Differences in HIV-1 subtype distribution in the patient pop-
ulations may account for these discrepancies. Although
DTG-S mutations neither confer measurable resistance to
DTG in vitro [3,5] nor appear to reduce response to DTG in
vivo [Vavro C, Underwood M, Madsen H et al. Polymor-
phisms at position 101 and 124 in the HIV-1 integrase (IN)
gene: lack of effects on susceptibility to S/GSK1349572. Fifti-
eth Interscience Conference on Antimicrobial Agents and
Chemotherapy, Boston, MA, 2010. Abstract H-935], it can-
not be excluded that they play a role in the acquisition or
modulation of resistance to DTG. Analysis of data derived
from DTG therapy is required to clarify this possibility.
TABLE 1. Prevalence of integrase mutations related to resistance to dolutegravir in raltegravir-naı¨ve and raltegravir-pretreat-
ed patients. Double and triple mutants involving codons 138, 140, 148 and 155 are shown only when detected at least in one
sequence
Mutations group Mutation(s)
Raltegravir-naı¨ve
patients (n = 440)
Raltegravir treated
patients (n = 120)
p (Fisher exact test)No. of cases % No. of cases %
DTG-S L101I 224 50.9 61 50.8 1.000
T124A 106 24.1 20 16.7 0.108
S153F 0 0.00 0 0.0 1.000
S153Y 0 0.00 0 0.0 1.000
L101I/T124A 67 15.2 13 10.8 0.243
Any of L101I T124A S153FY 263 59.8 68 56.7 0.600
MK-2048-S G118R 0 0.0 0 0.0 1.000
RTG-S E138A/G140S/Q148H 0 0.0 3 2.5 0.009
E138K/G140A/Q148K 0 0.0 1 0.8 0.214
E138K/G140S/Q148H 0 0.0 2 1.7 0.045
E138K/G140S/Q148R 0 0.0 1 0.8 0.214
G140A/Q148R 0 0.0 2 1.7 0.045
G140S/Q148H 0 0.0 21 17.5 <0.0001
G140S/Q148R/N155H 0 0.0 1 0.8 0.214
Q148H/N155H 0 0.0 1 0.8 0.214
Any combination 138/148 (plus others) 0 0.0 7 5.8 <0.0001
Any combination 140/148 (plus others) 0 0.0 31 25.8 <0.0001
Any combination 148/155 (plus others) 0 0.0 2 1.7 0.045
DTG-S, selected by dolutegravir in vitro; MK-2048-S, selected by MK-2048 in vitro; RTG-S, selected by raltegravir in vitro and/or in vivo.
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RTG-S mutants were not detected as natural polymor-
phisms in RTG- naı¨ve patients, thereby conﬁrming previous
reports [9,10]. By contrast, major IN mutations at codons
143, 148 or 155 were detected in 70 of the 120 RTG failures
and RTG-S double and triple mutants were detected in less
than half of these 70 patients. The relatively high rate of RTG
failures in the absence of IN mutations may be explained by
treatment adherence issues or some other unexplained mech-
anism(s); however, this observation has been commonly
reported in previous RTG treatment studies [6]. Reversion
from drug-resistant to wild-type virus cannot explain a fre-
quent lack of RTG resistance mutations at failure in our case
ﬁle because only 8 of the 120 (6.7%) post-RTG sequences
were obtained following RTG discontinuation. The median
time elapsed between RTG interruption and genotyping in
these cases was only 4 weeks and three of the eight
sequences indeed showed major RTG resistance mutations.
As many as 21 of the 32 RTG-S variants were G140S/Q148H
mutants, which were originally reported to result in lower
changes in DTG IC50 with respect to the more resistant iso-
lates containing Q148R (ﬁve cases in our ﬁle) [3]. However, a
more recent work showed similar DTG IC50 values for the
Q148H and Q148R mutants [5]. By contrast, the mutants
E138K/Q148K, Q148R/N155H and E138A/G140S/Q148H,
previously reported to have the greatest changes in DTG IC50
[3,5], were detected in only one, no and three cases, respec-
tively. In the absence of a validated clinical cut-off for DTG
fold resistance, it is currently difﬁcult to estimate what pro-
portion of patients failing RTG would beneﬁt from a second-
line use of DTG. The recent 24-week analysis of the pilot Vik-
ing study [Soriano V, Cox J, Eron JJ, et al. Dolutegravir (DTG,
S/GSK1349572) treatment of subjects with raltegravir (RAL)
resistance: viral suppression at week 24 in the Viking study.
13th European AIDS Conference (EACS 2011). Belgrade,
October 12–15, 2011. Abstract PS1/2] suggests that DTG can
suppress viraemia in most of the RTG-S cases provided the
twice-daily schedule is used. While current data support suc-
cessful use of DTG as both a ﬁrst and second-line INI, more
extensive and prolonged treatment data are required to
deﬁne the full potential of this next-generation INI.
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